Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Short-term Activity Ratios (Summary)

Abbott Laboratories, short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Turnover Ratios
Inventory turnover
Receivables turnover
Payables turnover
Working capital turnover
Average No. Days
Average inventory processing period
Add: Average receivable collection period
Operating cycle
Less: Average payables payment period
Cash conversion cycle

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The analyzed period is characterized by a general deceleration in operational efficiency, specifically regarding the movement of inventory and the collection of receivables, which has led to an expansion of the overall cash conversion cycle.

Inventory Management Efficiency
A downward trend in inventory turnover is evident, declining from 3.36 in March 2022 to a low of 2.62 in June 2023, with a subsequent stabilization around 2.82 by March 2026. This decline is mirrored by the average inventory processing period, which increased from 109 days to a peak of 139 days in June 2023. While there was a slight improvement toward the end of 2024, the overall trend indicates that inventory is being held longer before being converted into sales.
Receivables and Collection Performance
Receivables turnover exhibited a steady decline following a peak of 7.03 in September 2022, falling to 5.50 by March 2026. This erosion in turnover efficiency is directly reflected in the average receivable collection period, which extended from 59 days to 66 days. This suggests a lengthening of the time required to convert credit sales into cash.
Payables and Working Capital Utilization
The payables turnover ratio remained relatively stable throughout the period, fluctuating between 4.02 and 4.69, with the average payables payment period generally hovering between 78 and 91 days. Working capital turnover showed significant volatility, moving between 3.63 and 4.83 for much of the period before experiencing a sharp increase to 6.33 in March 2026, indicating a substantial increase in sales efficiency relative to the working capital invested at that specific point.
Operating and Cash Conversion Cycles
The operating cycle expanded from 168 days in March 2022 to 195 days by March 2026, driven by the cumulative delays in both inventory processing and receivable collection. Consequently, the cash conversion cycle saw a marked increase, rising from 77 days to a peak of 118 days in June 2025, before settling at 108 days. This trend indicates that more capital is tied up in the operating process for longer durations than in the preceding years.

Turnover Ratios


Average No. Days


Inventory Turnover

Abbott Laboratories, inventory turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of products sold, excluding amortization of intangible assets
Inventories
Short-term Activity Ratio
Inventory turnover1
Benchmarks
Inventory Turnover, Competitors2
Intuitive Surgical Inc.
Medtronic PLC

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Inventory turnover = (Cost of products sold, excluding amortization of intangible assetsQ1 2026 + Cost of products sold, excluding amortization of intangible assetsQ4 2025 + Cost of products sold, excluding amortization of intangible assetsQ3 2025 + Cost of products sold, excluding amortization of intangible assetsQ2 2025) ÷ Inventories
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a period of declining inventory efficiency from early 2022 through early 2024, followed by a phase of stabilization and moderate recovery. The inventory turnover ratio experienced a notable contraction, shifting from a high of 3.37 in September 2022 to a low of 2.62 in June 2023, indicating a slowdown in the rate at which inventory was converted into sales.

Inventory Turnover Ratio Trends
A downward trend is evident throughout 2022 and 2023, with the ratio falling from 3.36 in March 2022 to 2.65 by March 2024. This decline suggests an accumulation of stock relative to the cost of products sold. A recovery period began in 2024, peaking at 3.02 in December 2024, before stabilizing between 2.73 and 2.98 throughout 2025 and early 2026.
Inventory Level Dynamics
Inventory balances showed a general upward trajectory, increasing from 5,691 million US$ in March 2022 to a peak of 6,954 million US$ in June 2025. The expansion of inventory levels during 2023 and 2024 contributed significantly to the reduction in the turnover ratio. A sharp, temporary reduction in inventories to 6,194 million US$ in December 2024 corresponds directly with the period's highest efficiency peak of 3.02.
Cost of Products Sold (COPS) Stability
The cost of products sold, excluding amortization, remained relatively stable, fluctuating primarily between 4,331 million US$ and 5,075 million US$. Because COPS did not experience drastic shifts, the volatility in the inventory turnover ratio is primarily attributed to changes in the management and volume of inventory holdings rather than significant fluctuations in production costs or sales volume.
Operational Efficiency Insights
The data indicates a transition from high efficiency in 2022 to a period of inventory bloating in 2023. The subsequent recovery observed from late 2024 through 2025 suggests a correction in inventory management strategies, bringing the turnover ratio back toward a range of 2.80 to 3.00, which represents a more balanced operating cycle compared to the lows of 2023.

Receivables Turnover

Abbott Laboratories, receivables turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net sales
Trade receivables, less allowances
Short-term Activity Ratio
Receivables turnover1
Benchmarks
Receivables Turnover, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Receivables turnover = (Net salesQ1 2026 + Net salesQ4 2025 + Net salesQ3 2025 + Net salesQ2 2025) ÷ Trade receivables, less allowances
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a divergent relationship between sales recovery and collection efficiency from March 2022 through March 2026.

Net Sales Performance
A contraction in net sales was observed during the first year of the period, falling from 11,895 million USD in March 2022 to a trough of 9,747 million USD in March 2023. Subsequent quarters show a consistent recovery trend, with sales peaking at 11,459 million USD in December 2025 before a slight moderation to 11,164 million USD by March 2026.
Trade Receivables Dynamics
Trade receivables exhibited a period of decline until March 2023, reaching a minimum of 6,020 million USD. Following this point, a persistent upward trajectory is evident, with balances climbing steadily to 8,210 million USD by March 2026. This growth indicates a significant increase in the volume of outstanding credit extended to customers over the latter half of the analyzed period.
Receivables Turnover Efficiency
The receivables turnover ratio experienced an initial increase, peaking at 7.03 in September 2022. From March 2023 onward, a sustained downward trend is observed, with the ratio declining to 5.50 by March 2026. This deterioration suggests a slowing of the collection cycle and a decrease in the efficiency of converting accounts receivable into cash, as the growth in the receivables balance outpaced the growth in net sales.

Payables Turnover

Abbott Laboratories, payables turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of products sold, excluding amortization of intangible assets
Trade accounts payable
Short-term Activity Ratio
Payables turnover1
Benchmarks
Payables Turnover, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Payables turnover = (Cost of products sold, excluding amortization of intangible assetsQ1 2026 + Cost of products sold, excluding amortization of intangible assetsQ4 2025 + Cost of products sold, excluding amortization of intangible assetsQ3 2025 + Cost of products sold, excluding amortization of intangible assetsQ2 2025) ÷ Trade accounts payable
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of payables turnover reveals a consistent pattern of stability punctuated by recurring seasonal fluctuations over the period from March 2022 to March 2026.

Payables Turnover Ratio Trends
The turnover ratio fluctuates within a narrow range between 4.02 and 4.69. A distinct cyclical trend is observable, with the ratio consistently peaking in the third quarter of each calendar year, reaching highs of 4.67 in September 2022, 4.55 in September 2023, 4.54 in September 2024, and 4.69 in September 2025. These periodic peaks indicate intervals of accelerated payments to suppliers or a temporary reduction in outstanding obligations relative to the cost of products sold.
Correlation between Costs and Liabilities
The cost of products sold exhibited relative stability, with a minimum of 4,331 million US dollars in March 2023 and a maximum of 5,075 million US dollars in September 2025. Trade accounts payable generally moved in tandem with these costs, fluctuating between 3,961 million and 4,757 million US dollars. This correlation suggests that the company maintains a disciplined and predictable procurement-to-payment cycle.
Analysis of Recent Variance
A divergence is noted in the final quarter of the sequence. Between December 2025 and March 2026, the payables turnover ratio declined from 4.56 to 4.22. This decrease is driven by a significant increase in trade accounts payable, which rose from 4,240 million to 4,679 million US dollars, despite the cost of products sold remaining nearly constant at approximately 4,900 million US dollars. This shift indicates a slowing of the payment velocity, effectively increasing the company's short-term financing from its suppliers.

Working Capital Turnover

Abbott Laboratories, working capital turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Current assets
Less: Current liabilities
Working capital
 
Net sales
Short-term Activity Ratio
Working capital turnover1
Benchmarks
Working Capital Turnover, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Working capital turnover = (Net salesQ1 2026 + Net salesQ4 2025 + Net salesQ3 2025 + Net salesQ2 2025) ÷ Working capital
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a period of relative stability in working capital management followed by a significant increase in efficiency during the final observed quarter. Working capital turnover ratios generally fluctuated between 3.63 and 4.83 from March 2022 through December 2025, indicating a consistent relationship between the company's liquid assets minus current liabilities and its ability to generate revenue.

Working Capital Trends
A general downward trajectory in working capital is observed, starting from a peak of 12,564 million USD in June 2022. While there were intermittent fluctuations, the level of working capital declined to 8,355 million USD by March 2024. A subsequent recovery occurred through mid-2025, peaking again at 11,029 million USD in June 2025, before experiencing a sharp contraction to a period low of 7,131 million USD by March 31, 2026.
Net Sales Performance
Net sales exhibited a U-shaped pattern during the first half of the analyzed period, declining from 11,895 million USD in March 2022 to a trough of 9,747 million USD in March 2023. Following this period, a steady recovery was noted, with sales increasing consistently to reach a peak of 11,459 million USD in December 2025, before a slight moderation to 11,164 million USD in the final quarter.
Working Capital Turnover Analysis
The working capital turnover ratio remained largely range-bound for the majority of the period, suggesting a stable operational cycle. The ratio experienced a modest increase from 4.13 in March 2022 to 4.83 in March 2024, reflecting a period where sales were maintained or grown while working capital requirements were reduced. A notable surge is observed in the final period ending March 31, 2026, where the ratio reached 6.33. This spike is primarily attributed to the substantial reduction in working capital occurring simultaneously with stable net sales, indicating a significant increase in the efficiency of asset utilization to generate revenue.

Overall, the data indicates an optimization of short-term assets. The divergence between declining working capital and recovering net sales toward the end of the period suggests a leaner operational structure and improved liquidity management.


Average Inventory Processing Period

Abbott Laboratories, average inventory processing period calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Inventory turnover
Short-term Activity Ratio (no. days)
Average inventory processing period1
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
Intuitive Surgical Inc.
Medtronic PLC

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The analysis of inventory management metrics from March 2022 through March 2026 reveals a distinct period of declining efficiency followed by a partial stabilization. The inventory processing cycle experienced a marked extension starting in early 2023, which coincided with a corresponding decrease in the inventory turnover ratio.

Inventory Turnover Trends
The inventory turnover ratio remained relatively stable throughout 2022, fluctuating between 3.10 and 3.37. A downward trend emerged in early 2023, with the ratio reaching a minimum of 2.62 by June 2023. Although a recovery occurred toward the end of 2024, peaking at 3.02 in December, the ratio subsequently entered a period of volatility, closing at 2.82 in March 2026.
Average Inventory Processing Period
The time required to process inventory shifted from a range of 108 to 118 days in 2022 to a significant peak of 139 days in June 2023. This extension indicates a slowdown in inventory velocity and an increase in the working capital cycle. A corrective phase is observed in late 2024, where the processing period dropped to 121 days, before stabilizing between 123 and 134 days throughout 2025 and the first quarter of 2026.
Operational Correlation
A consistent inverse correlation is observed between the turnover ratio and the processing period. The expansion of the processing period during 2023 and early 2024 suggests either a decrease in demand relative to stock levels or a strategic accumulation of inventory. The subsequent reduction in days by December 2024 points to an improvement in inventory throughput, although the efficiency levels failed to return to the baseline established in early 2022.

Average Receivable Collection Period

Abbott Laboratories, average receivable collection period calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Receivables turnover
Short-term Activity Ratio (no. days)
Average receivable collection period1
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


An analysis of the short-term operating activity ratios reveals a general decline in receivables management efficiency from early 2022 through early 2026. While a period of improved collection efficiency was observed during the latter half of 2022, this trend reversed in 2023 and continued through the end of the analyzed period, resulting in a longer cash conversion cycle for receivables.

Receivables Turnover
The receivables turnover ratio exhibited an initial upward trend, peaking at 7.03 in September 2022. However, a consistent downward trajectory followed, with the ratio declining to 5.50 by March 31, 2026. This sustained decrease indicates a reduction in the frequency with which the company collects its average accounts receivable balance over the specified timeframe.
Average Receivable Collection Period
The collection period reflects an inverse relationship with the turnover ratio. Efficiency peaked between September and December 2022, where the collection period reached its lowest point of 52 days. Following this period, the collection cycle lengthened steadily, reaching a maximum of 68 days in September 2025 before settling at 66 days by March 31, 2026. This represents a net increase of 7 days in the average time required to convert credit sales into cash compared to the starting period.
Comparative Trend Analysis
The data shows two distinct phases of operational activity. The first phase, spanning March 2022 to December 2022, was characterized by improving liquidity metrics. The second phase, spanning from March 2023 to March 2026, is characterized by a gradual erosion of collection efficiency. The most significant deterioration occurred between March 2024 and September 2025, during which the collection period rose from 60 days to 68 days, coinciding with the turnover ratio dropping from 6.11 to 5.39.

Operating Cycle

Abbott Laboratories, operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period
Average receivable collection period
Short-term Activity Ratio
Operating cycle1
Benchmarks
Operating Cycle, Competitors2
Intuitive Surgical Inc.
Medtronic PLC

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =

2 Click competitor name to see calculations.


The operating cycle reflects a general expansion in the time required to convert inventory into cash from the beginning of the period through March 31, 2026. This lengthening is driven by synchronized increases in both the inventory processing period and the receivable collection period, indicating a slower turnover of working capital.

Average Inventory Processing Period
A general upward trend is observed, starting from 109 days in March 2022 and peaking at 139 days in June 2023. While the period experienced a notable contraction to 121 days by December 2024, it remained elevated compared to 2022 levels, fluctuating between 123 and 134 days through the remainder of the period. This suggests a persistent increase in the duration that inventory is held before being sold.
Average Receivable Collection Period
The collection period remained relatively stable between 52 and 60 days throughout 2022 and 2023. However, a gradual increase became evident starting in 2024, with the period climbing to a peak of 68 days in September 2025 before settling at 66 days by March 2026. This trend indicates a deceleration in the speed of cash recovery from customers.
Operating Cycle Total
The total operating cycle expanded from 168 days in March 2022 to a peak of 201 days in June 2025. The most significant expansion occurred between late 2022 and early 2024, where the cycle shifted from an average of approximately 165 days to nearly 200 days. Despite a temporary dip to 181 days in December 2024, the cycle concluded at 195 days in March 2026, representing a net increase of 27 days over the analyzed timeframe.

The data indicates that the widening of the operating cycle is primarily attributed to slower inventory throughput, although the recent steady climb in receivable collection days has contributed to maintaining these elevated levels. The lack of a return to 2022 efficiency levels suggests a structural change in operating activity or a strategic shift in inventory management and credit terms.


Average Payables Payment Period

Abbott Laboratories, average payables payment period calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Payables turnover
Short-term Activity Ratio (no. days)
Average payables payment period1
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity indicates a stable pattern in the management of accounts payable from March 2022 through March 2026. The company demonstrates a consistent approach to settling supplier obligations, with fluctuations remaining within a narrow and predictable range.

Payables Turnover Trends
The payables turnover ratio fluctuated between a low of 4.02 in March 2022 and a peak of 4.69 in September 2025. A period of relative stability was observed throughout 2023 and 2024, where the ratio generally remained between 4.19 and 4.55. The most recent data point from March 2026 shows a decrease to 4.22, suggesting a slight deceleration in the frequency of payable settlements.
Average Payables Payment Period
The average time taken to settle payables experienced a general contraction from an initial 91 days in March 2022 to a baseline primarily ranging between 78 and 87 days. The most efficient payment cycles occurred in September 2022 and September 2025, both reaching a minimum of 78 days. Following this period of efficiency, the payment duration increased to 87 days by March 2026, indicating a moderate extension of the payment cycle.
Operational Correlation and Working Capital Management
A consistent inverse relationship is maintained between the turnover ratio and the payment period; peaks in turnover directly correspond with the shortest payment durations. The lack of extreme variance in these metrics suggests a disciplined working capital strategy, aiming to balance cash preservation with the maintenance of supplier relationships without significant deviations in payment behavior.

Cash Conversion Cycle

Abbott Laboratories, cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period
Average receivable collection period
Average payables payment period
Short-term Activity Ratio
Cash conversion cycle1
Benchmarks
Cash Conversion Cycle, Competitors2
Intuitive Surgical Inc.
Medtronic PLC

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + =

2 Click competitor name to see calculations.


The cash conversion cycle exhibits a notable upward trend over the analyzed period, expanding from 77 days in March 2022 to 108 days by March 2026. This expansion indicates a longer duration between the initial cash outlay for inventory and the final receipt of cash from sales, suggesting a decrease in overall operating liquidity efficiency.

Average Inventory Processing Period
A significant increase in the time required to process inventory is observed, particularly between early 2022 and mid-2023, where the period rose from 109 days to a peak of 139 days in June 2023. Although a temporary contraction occurred in late 2024, reaching a low of 121 days in December, the period remained elevated relative to the 2022 baseline, ending at 129 days in March 2026.
Average Receivable Collection Period
The collection period remained relatively stable during 2022, fluctuating between 52 and 59 days. However, a gradual and steady upward trend emerged starting in 2023, with the period climbing from 53 days in March 2023 to 66 days by March 2026. This trajectory indicates a slowing in the rate of customer payments.
Average Payables Payment Period
The payment period for accounts payable demonstrated the least volatility among the three components. After an initial decrease from 91 days in March 2022 to 82 days in March 2023, the metric fluctuated within a narrow range of 78 to 87 days. The lack of a significant upward trend in payables payment suggests that the company did not extend its credit terms with suppliers to offset the increases in inventory and receivable periods.

The overall extension of the cash conversion cycle is primarily driven by the simultaneous increase in inventory holding times and a slower collection of receivables. Because the payables payment period remained relatively flat, it provided no offsetting benefit to the working capital cycle, resulting in a net increase of 31 days in the total cash conversion cycle from the start to the end of the analyzed period.